Barclays’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Sell |
74,977
-1,037,281
| -93% | -$22.4M | ﹤0.01% | 2489 |
|
|
2025
Q4 | $26.5M | Buy |
1,112,258
+935,178
| +528% | +$19.1M | 0.01% | 1084 |
|
|
2025
Q3 | $2.41M | Sell |
177,080
-69,590
| -28% | -$724K | ﹤0.01% | 2755 |
|
|
2025
Q2 | $2.01M | Buy |
246,670
+63,939
| +35% | +$546K | ﹤0.01% | 2840 |
|
|
2025
Q1 | $1.43M | Buy |
182,731
+69,693
| +62% | +$808K | ﹤0.01% | 2890 |
|
|
2024
Q4 | $1.68M | Sell |
113,038
-5,655
| -5% | -$92.4K | ﹤0.01% | 3031 |
|
|
2024
Q3 | $1.81M | Buy |
118,693
+39,015
| +49% | +$615K | ﹤0.01% | 2930 |
|
|
2024
Q2 | $1.21M | Sell |
79,678
-108,193
| -58% | -$1.75M | ﹤0.01% | 2485 |
|
|
2024
Q1 | $3.55M | Sell |
187,871
-15,022
| -7% | -$260K | ﹤0.01% | 2085 |
|
|
2023
Q4 | $3.88M | Sell |
202,893
-267,883
| -57% | -$4.28M | ﹤0.01% | 2347 |
|
|
2023
Q3 | $8.45M | Buy |
470,776
+304,683
| +183% | +$6.12M | 0.01% | 1064 |
|
|
2023
Q2 | $3.37M | Buy |
166,093
+3,642
| +2% | +$69.3K | ﹤0.01% | 1587 |
|
|
2023
Q1 | $2.96M | Buy |
162,451
+36,413
| +29% | +$696K | ﹤0.01% | 1911 |
|
|
2022
Q4 | $2.61M | Sell |
126,038
-42,672
| -25% | -$1.17M | ﹤0.01% | 2070 |
|
|
2022
Q3 | $4.41M | Buy |
168,710
+133,006
| +373% | +$3.52M | ﹤0.01% | 1237 |
|
|
2022
Q2 | $905K | Buy |
35,704
+5,128
| +17% | +$126K | ﹤0.01% | 2450 |
|
|
2022
Q1 | $965K | Sell |
30,576
-27,336
| -47% | -$916K | ﹤0.01% | 2438 |
|
|
2021
Q4 | $2.34M | Buy |
57,912
+2,102
| +4% | +$81.5K | ﹤0.01% | 2281 |
|
|
2021
Q3 | $1.95M | Buy |
55,810
+49,753
| +821% | +$1.55M | ﹤0.01% | 2383 |
|
|
2021
Q2 | $166K | Sell |
6,057
-66,514
| -92% | -$1.9M | ﹤0.01% | 3634 |
|
|
2021
Q1 | $2.04M | Buy |
72,571
+26,497
| +58% | +$922K | ﹤0.01% | 2256 |
|
|
2020
Q4 | $1.2M | Sell |
46,074
-11,911
| -21% | -$288K | ﹤0.01% | 2627 |
|
|
2020
Q3 | $995K | Buy |
57,985
+5,836
| +11% | +$130K | ﹤0.01% | 2701 |
|
|
2020
Q2 | $1.29M | Buy |
52,149
+37,235
| +250% | +$1M | ﹤0.01% | 2526 |
|
|
2020
Q1 | $207K | Sell |
14,914
-22,323
| -60% | -$278K | ﹤0.01% | 4266 |
|
|
2019
Q4 | $376K | Buy |
37,237
+15,024
| +68% | +$126K | ﹤0.01% | 4534 |
|
|
2019
Q3 | $203K | Sell |
22,213
-28,392
| -56% | -$228K | ﹤0.01% | 4955 |
|
|
2019
Q2 | $402K | Buy |
50,605
+40,134
| +383% | +$402K | ﹤0.01% | 4521 |
|
|
2019
Q1 | $131K | Buy |
10,471
+8,871
| +554% | +$96.3K | ﹤0.01% | 5151 |
|
|
2018
Q4 | $17K | Sell |
1,600
-4,026
| -72% | -$47K | ﹤0.01% | 5977 |
|
|
2018
Q3 | $78K | Buy |
5,626
+2,371
| +73% | +$30.2K | ﹤0.01% | 5774 |
|
|
2018
Q2 | $41K | Buy |
+3,255
| New | +$51.1K | ﹤0.01% | 5758 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Barclays's RCUS Position: Q1 2026 in Review
Barclays reduced its Arcus Biosciences (RCUS) stake by 93% in Q1 2026, selling an estimated $22.4M and leaving 74,977 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2489.
Barclays first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. The position peaked at $26.5M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Barclays held 74,977 shares of Arcus Biosciences worth $1.62M as of Q1 2026.
- Barclays sold 1,037,281 Arcus Biosciences shares in Q1 2026, an estimated $22.4M.
- Arcus Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2489 holding.
- Barclays first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- Barclays's Arcus Biosciences position peaked at $26.5M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.